Business
Abbisko Therapeutics’ CSF-1R Inhibitor Pimicotinib Approved by the China NMPA, Addressing the Treatment Gap for Tenosynovial Giant Cell Tumor
Based on the positive global Phase III MANEUVER study, the National Medical Products Administration (NMPA) has granted the world’s first regulatory approval for pimicotinib, the first domestically developed systemic therapy for the treatment of Tenosynovial Giant Cell Tumor (TGCT), to our partner Merck KGaA, Darmstadt, Germany, which holds worldwide commercialization rightsPimicotinib, a Class 1 innovative drug discovered and developed by Abbisko Therapeutics, received zero-deficiency approval i
About this update from Merck Kgaa
[{"type":"image","alt":"Abbisko Therapeutics Co., Ltd.","displaySize":"","headline":null,"caption":"Abbisko Therapeutics Co., Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":102,"url":"https://media.zenfs.com/en/globenewswire.com/1821471e9491ea0fef219fb2b7a46407"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YO9sdbQktzVDfPTKa6_Mdg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1821471e9491ea0fef219fb2b7a46407","width":300,"height":102}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Based on the positive global Phase III MANEUVER study, the National Medical Products Administration (NMPA) has granted the world’s first regulatory approval for pimicotinib, the first domestically developed systemic therapy for the treatment of Tenosynovial Giant Cell Tumor (TGCT), to our partner Merck KGaA, Darmstadt, Germany, which holds worldwide commercialization rights","length":376,"tagName":"p"}]},{"val":[{"type":"text","content":"Pimicotinib, a Class 1 innovative drug discovered and developed by Abbisko Therapeutics, received zero-deficiency approval in just over six months following NDA acceptance. During the review, the Center for Food and Drug Inspection (CFDI) conducted its first-ever overseas clinical site inspection for pimicotinib, which it successfully passed. This outcome reflects Abbisko’s rigorous R&D standards and regulators’ strong recognition of the therapy’s clinical value and data quality.","length":488,"tagName":"p"}]},{"val":[{"type":"text","content":"Pimicotinib’s approval for the treatment of TGCT marks a key milestone in the company’s advancement from pioneering innovative research to first product commercialization.","length":171,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1035,"olType":false},{"type":"text","content":"SHANGHAI, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Following this approval, Merck KGaA, Darmstadt, German...